Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men.
Skorupskaite. Karolina K; George. Jyothis T JT; Veldhuis. Johannes D JD; Millar. Robert P RP; Anderson. Richard A RA
Key Findings
- An oral NK3R antagonist (MLE4901) taken twice daily for a week sharply reduced LH, FSH, and testosterone levels in healthy men.
- LH showed a biphasic drop: a big fall after 24 hours, partial rebound, then another decline by day 7.
- Kisspeptin‑10 still provoked a similar LH surge before and during NK3R antagonism, indicating its action is downstream of NK3R.
- LH pulse frequency did not change, but overall pulse amplitude and basal secretion were strongly suppressed.
Practical Outcomes
- For biohackers aiming to boost testosterone or reproductive hormones, using an NK3R antagonist would be counter‑productive. Kisspeptin‑10 can still trigger LH release even if NK3 signaling is blocked, but the overall hormone environment remains suppressed, so any protocol that includes NK3R blockers should be avoided for performance or longevity goals.
Summary
In a tiny study of six healthy men, blocking the NK3 receptor lowered the body's natural production of LH, FSH, and testosterone, but a single dose of kisspeptin‑10 still caused a spike in LH even while the blocker was active. This shows the NK3 pathway sits upstream of kisspeptin in controlling reproductive hormones.
Abstract
Patients with mutations of neurokinin B (NKB) and its receptor show hypogonadotrophic hypogonadism, but there is little evidence for the importance of this pathway in reproductive function in normal men, or its functional hierarchy with kisspeptin. An open label study wherein men (n = 6) were administered the NK3R antagonist MLE4901 40 mg orally twice a day for 7 days. Kisspeptin-10 (0.3 μg/kg iv bolus) was given before and on day 7 of NK3R antagonist treatment. Subjects were healthy men. Reproductive hormones were measured before and during the NK3R antagonist administration, including frequent sampling on two occasions for analysis of pulsatile LH secretion. LH, FSH and testosterone secretion were decreased during NK3R antagonist administration. LH showed a biphasic response, being reduced after 24 hours of treatment (4.5 ± 0.6 IU/L pretreatment to 1.7 ± 0.2 IU/L, P < .05), with partial recovery thereafter, but it was again decreased on day 7 (2.5 ± 0.6 IU/L, P < .05 vs pretreatment). FSH secretion was also suppressed, with a similar temporal pattern to that of LH. Testosterone secretion was decreased from 24 hours (18.4 ± 1.6 pretreatment vs 5.6 ± 1.5 nmol/L, P < .01) and remained suppressed throughout the treatment period. Analysis of LH pulsatility showed that both basal and pulsatile LH secretion were markedly suppressed but there was no detected change in LH pulse frequency. Kisspeptin-10 stimulated LH secretion, with similar responses before and during NK3R antagonist administration. These data demonstrate a central role for NKB/NK3R in the physiological regulation of reproductive function in men, and that this is functionally upstream of kisspeptin-mediated GnRH secretion.
Study Information
pubmed
2017
2017-09-05T00:00:00.000Z
10.1111/cen.13445
20
42